New drug aims to save hearts in duchenne muscular dystrophy
NCT ID NCT03340675
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an oral drug called ifetroban in 46 males aged 7 and older with Duchenne muscular dystrophy (DMD). The goal was to see if the drug is safe and can help prevent or treat heart problems, which are a leading cause of death in DMD. Participants received either ifetroban or a placebo daily, and researchers monitored side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ifetroban (oral drug)
What this could lead to
If it works, this could point toward a treatment to protect the heart in Duchenne muscular dystrophy, potentially extending life.
What could go wrong
This is a small Phase 2 trial with only 46 participants, so results may not be conclusive. The drug may not improve heart function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY, DILATED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30341, United States
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Kennedy Krieger Institute
Baltimore, Maryland, 21205, United States
-
Lurie Children's Hospital
Chicago, Illinois, 60611, United States
-
Mattel Children's Hospital
Los Angeles, California, 90095, United States
-
Monroe Carrell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, 37232, United States
-
Riley Children's Hospital
Indianapolis, Indiana, 46202, United States
-
Saint. Louis Children's Hospital
St Louis, Missouri, 63110, United States